Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute
Open Access
- 16 August 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (10) , e1883-e1886
Abstract
Despite expanding indications for immunotherapeutic agents, there is limited understanding about their clinical effects on pregnancy outcomes. Generally, pregnant patients with cancer are excluded from clinical trials, and inadvertent pregnancies on trial result in patients being taken off because of concerns for fetal toxicity. To answer this question of pregnancy outcomes on immunotherapy-based trials, we performed a retrospective analysis of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-Adverse Event Reporting System for unexpected pregnancies during NCI-CTEP–sponsored immunotherapy clinical trials between 2011 and 2020. We identified nine female patients who had unexpected pregnancies, of whom seven chose to take their pregnancies to term. All seven pregnancies resulted in vaginal births of apparently normal infants. This is the first report of pregnancy outcomes in multiple female patients exposed to immunotherapy. Our data suggest the need for further research to better evaluate and define contraception recommendations during immunotherapy treatment for cancer.Keywords
This publication has 13 references indexed in Scilit:
- A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapySeminars in Oncology, 2018
- Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapySeminars in Oncology, 2018
- A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumabSeminars in Oncology, 2017
- The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic ratsScientific Reports, 2016
- An Evaluation of the Impact of PD‐1 Pathway Blockade on Reproductive Safety of Therapeutic PD‐1 InhibitorsBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2016
- Mean Age of Mothers is on the Rise: United States, 2000-2014.2016
- Role of PD1/PDL1 pathway, and TH17 and treg cells in maternal tolerance to the fetusBiomedical Journal, 2015
- Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancyBest Practice & Research Clinical Obstetrics & Gynaecology, 2011
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- A critical role for the programmed death ligand 1 in fetomaternal toleranceJournal of Experimental Medicine, 2005